Biopôle Clermont-Limagne
Technology park for life sciences
Year of creation : 2003
Statut : limited company
Size : 6
% of CA dedicated to R&D : NC
Patents (number of) : 6

Contact details

Biopôle Clermont-Limagne

5 rue Emile Duclaux

63360 Saint-Beauzire



Contact : Stéphane Gobron
Phone : +33 473 449 430
Email : sgobron@neuronax.com
Website : www.neuronax.com

Neuronax

Development of candidate-drugs supporting neural repair in order to treat traumatic or degenerative diseases


Neuronax’s aim is to develop therapeutic products supporting neural repair in order to treat traumatic or severe degenerative disorders of the central nervous system (CNS) and contribute to improve neurological function, and then quality of life of patients.


Neuronax is focusing its development effort firstly on spinal cord injuries (SCI), a huge unmet medical need without efficient treatment option available. Preclinical research has shown that NX210 is able to rescue neurons from cell death and to stimulate the regrowth of nerve fibers leading to improve functional recovery in SCI. Recently, Neuronax successfully filed an Investigational New Drug (IND) application with French and Belgium agencies enabling the company to proceed with a Phase 1 study that will provide pharmacokinetic and tolerability data in spinal cord injured patients.